Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVX000222 phase 3 cardiovascular outcomes trial in high-risk type 2 diabetes with coronary artery disease
NL-OMON47920Phase 3Active, not recruiting
- Sponsor
- Resverlogix Corp.
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis comparing RVX000222 with Placebo (2 arms). Primary endpoint: Time to first narrowly defined major adverse cardiovascular event. Started Sep 2017; status: active, not recruiting.
02
Drugs
apabetalone
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON47920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47920.